ABT-072是非核苷<b>NS5B polymerase</b>的抑制劑,為治療HCV的有效候選藥。<BR><a href="https://www.medchemexpress.cn/PI4KIIIbeta-IN-10.html">PI4KIIIbeta-IN-10</a>產品描述:PI4KIIIbeta-IN-10 is the most potent PI4KIIIβ inhibitor currently reported, with very minor off-target inhibition of PI4KIIIβ related lipid kinases (IC50 = 3.6 nM).IC50 value: 3.6 nMTarget: PI4KIIIβin vitro: PI4KIIIbeta-IN-10 is the most potent PI4KIIIβ inhibitor currently reported, with very minor off-target inhibition of PI4KIIIβ related lipid kinases. PI4KIIIbeta-IN-10 shows weak inhibition of PI3KC2γ (IC50 1 μM), PI3Kα (10 μM), and PI4KIIIα (3 μM), and <20% inhibition at concentrations up to 20 μM for PI4K2α, PI4K2β, and PI3Kβ. PI4KIIIbeta-IN-10 is also the most effective antiviral compound in a cellular model of hepatitis C virus replication, with the best balance of antiviral potency and low cellular toxicity[1].<br><br><br><span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">公司介紹:MedChemExpress(MCE)專注于各種抑制劑、激動劑、API及化合物庫,總部位于美國新澤西,分別在瑞典和上海設有歐洲區(qū)子公司和亞洲區(qū)總代理,營銷網點遍及全球20多個國家地區(qū)。MCE經過多年努力已成為全球生物活性小分子領域的一流供應商, 產品涵蓋癌癥、神經科學、抗感染、表觀遺傳學等20個熱門研究領域,PI3K、MAPK等近千個細分靶點,超過4000個活性小分子化合物現(xiàn)貨,以及GPCR、API、離子通道等超過20種不同類型的化合物庫,同時提供從毫克到千克的專業(yè)定制合成服務。</span><br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"><span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">MCE 對每批產品都進行嚴格的LCMS和NMR檢驗,其產品已被全球近萬名客戶廣泛使用并發(fā)表大量文章、專利;</span><br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"><span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">MCE 定期增加各領域熱門抑制劑、激動劑,不斷擴增已有化合物庫,以滿足最新的科研需求;</span><br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"><span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">數(shù)千種產品在上海有充足備貨,24-48小時內送達客戶;</span><br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"><span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">大量產品提供免費試用裝;</span><span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">已為全球多個知名企業(yè)、院校構建各種定制型化合物庫。</span><br><br>產品鏈接:<a href="http://www.medchemexpress.cn/PI4KIIIbeta-IN-10.html">www.medchemexpress.cn/PI4KIIIbeta-IN-10.html</a><br><br></span><img style="width: 600.0px;height: 310.0px;" src="http://img.dxycdn.com/trademd/upload/userfiles/image/2014/08/A1408605159png_small.jpg" alt="">Purity:98%<BR>MWt:469.5533<BR>Formula:C24H27N3O5S<BR>SMILES:CS(=O)(NC1=CC=C(/C=C/C2=CC(N(C(N3)=O)C=CC3=O)=CC(C(C)(C)C)=C2OC)C=C1)=O<BR>Pathway:Anti-infection; <BR>Mechanisms:HCV; <BR>Research Area:Infection<BR>電話: 021-58955995<BR>網址: www.MedChemExpress.cn <BR>地址: 上海市浦東新區(qū)蔡倫路720號2號樓3層 |
ABT-072前沿研究進展
發(fā)布日期:2017-11-13 瀏覽次數(shù):0
核心提示:ABT-072是非核苷bNS5B polymerase/b的抑制劑,為治療HCV的有效候選藥。BRa href=https://www.medchemexpress.cn/PI4KIIIbeta-IN-
- 下一篇:暫無
- 上一篇:Irindalone前沿研究進展
行業(yè)動態(tài)
更多...
- ABT-072前沿研究進展 11-13
- Irindalone前沿研究進展 11-13
- Deramciclane前沿研究進展 11-13
- (E)-Crotylbarbital前沿研 11-13
- KDR-in-4前沿研究進展 11-13
- YM17E前沿研究進展 11-13
- Sigma-LIGAND-1前沿研究進 11-13
- Recilisib前沿研究進展 11-13
- MRZ 2-514前沿研究進展 11-13
- Abaperidone前沿研究進展 11-13